ALECENSA Distribution

Authorized Specialty Distributors and Specialty Pharmacies

Genentech BioOncology® Access Solutions for ALECENSA works with specialty pharmacies (SPs) to help patients receive their medicines.

An SP may provide the following services:

  • Reimbursement resources
  • Clinical services to support patients throughout their treatment
  • The ability to manage the specialty handling and shipping needs linked with many specialty therapies

You can work with your preferred SP or contact Genentech BioOncology Access Solutions to learn which SP the patient’s health insurance plan requires.

Distributor Telephone Fax Web Orders
AmerisourceBergen Drug Corporation

844-222-2273

816-464-4140 http://www.amerisourcebergendrug.com/home
Cardinal Health Distribution

855-625-4677

800-364-6198 (VA/DOD)

N/A www.cardinalhealth.com
McKesson US Pharmaceutical 877-625-2566 888-752-7626 https://connect.mckesson.com

 

Distributor Telephone Fax Web Orders
ASD Healthcare 800-746-6273 800-547-9413 www.asdhealthcare.com
Cardinal Health Specialty Distribution 800-926-3161 888-345-4916 specialtyonline.cardinalhealth.com
McKesson Plasma and Biologics (MPB) 877-625-2566 888-752-7626 https://connect.mckesson.com

 

Distributor Telephone Fax Web Orders
ASD Healthcare 800-746-6273
800-547-9413 www.asdhealthcare.com
Cardinal Health Specialty Distribution 800-926-3161 888-345-4916 specialtyonline.cardinalhealth.com
McKesson Specialty Health (Oncology) 800-482-6700 800-289-9285 mscs.mckesson.com
Oncology Supply 800-633-7555 800-248-8205 www.oncologysupply.com

 

Distributor Telephone Fax Web Orders
ASD Healthcare 800-746-6273 800-547-9413 www.asdhealthcare.com
Cardinal Health Specialty Distribution 800-926-3161 888-345-4916 specialtyonline.cardinalhealth.com
McKesson Plasma and Biologics 877-625-2566 888-752-7626 https://connect.mckesson.com
McKesson Specialty Health (Oncology) 800-482-6700 800-289-9285 mscs.mckesson.com
Oncology Supply 800-633-7555 800-248-8205 www.oncologysupply.com

 

Distributor Telephone Fax Web Orders
Absolute Pharmacy Care
787-892-8700
787-264-5800
www.absolutepharmacypr.com
Axium Healthcare Puerto Rico 787-780-7200 800-546-2163 www.AxiumPR.com
Cardinal Health Puerto Rico

800-981-4699

787-625-4200

787-625-4398 cardinalhealth.pr
Cesar Castillo 787-999-1616
787-720-1095 www.cesarcastillo.net
Special Care Pharmacy Services
787-781-4585
787-706-0405
specialcarepr.com
Distributor Telephone Fax Web Orders
Accredo 877-732-3431 888-302-1028 www.accredo.com
Advanced Care Scripts (ACS) 866-681-7131 866-679-7131 www.acs-rx.com
Aetna Specialty Pharmacy 866-782-2779 866-329-2779 https://www1.aetna.com/provider/contact_us.html
AllianceRx Walgreens Prime
888-347-3416 877-231-8302 www.alliancerxwp.com
Avella Specialty Pharmacy 877-546-5779 877-546-5780 www.avella.com
Biologics 800-850-4306 800-823-4506 www.biologicsinc.com
BriovaRx 855-427-4682 877-342-4596 www.BriovaRx.com
CVS/specialty 800-237-2767 800-323-2445 www.cvsspecialty.com
Onco360 877-662-6633 877-662-6355 www.onco360.com
US Bioservices 877-757-0667 888-418-7246 www.usbioservices.com

Genentech does not influence or advocate the use of any one specialty distributor or specialty pharmacy. We make no representation or guarantee of service or coverage of any item.

PAN=Patient Authorization and Notice of Request for Transmission of Health Information to Genentech Access Solutions and Genentech® Access to Care Foundation.

SMN=Statement of Medical Necessity.

Important Safety Information & Indication

Indication

ALECENSA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (mNSCLC) as detected by an FDA- approved test.

Important Safety Information

Hepatotoxicity: Monitor liver function tests every 2 weeks during the first 3 months of treatment, then once a month and as clinically indicated, with more frequent testing in patients who develop transaminase and bilirubin elevations. Based on the severity of the adverse reaction, withhold then dose reduce, or permanently discontinue ALECENSA.

Interstitial Lung Disease (ILD)/Pneumonitis: ILD/pneumonitis occurred in 0.7% of patients. Immediately withhold ALECENSA in patients diagnosed with ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis have been identified.

Renal Impairment: Renal impairment occurred in 8% of patients. Incidence of Grade ≥3 was 1.7%, of which 0.5% were fatal events. Based on the severity of the adverse reaction, withhold then dose reduce, or permanently discontinue ALECENSA.

Bradycardia: Monitor heart rate and blood pressure regularly. If symptomatic, withhold ALECENSA then dose reduce or permanently discontinue.

Severe Myalgia and Creatine Phosphokinase (CPK) Elevation: Advise patients to report any unexplained muscle pain, tenderness, or weakness. Assess CPK levels every 2 weeks for the first month of treatment and as clinically indicated in patients reporting symptoms. Based on the severity of the CPK elevation, withhold, then resume or dose reduce ALECENSA.

Embryo-Fetal Toxicity: ALECENSA can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ALECENSA and for 1 week following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with ALECENSA and for 3 months following the final dose.

Most Common Adverse Reactions: The most common adverse reactions (incidence ≥20%) were constipation (34%), fatigue (26%), myalgia (23%), edema (22%), and anemia (20%).

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see additional Important Safety Information in full Prescribing Information.